Products named in published studies
Clinics often tell you a product name. If it appears here, you can see what was actually tested, in whom, and how strong that evidence is.
| Product | Maker or sponsor | Made from | Where it was studied | Strongest evidence so far |
|---|---|---|---|---|
| ExoSCRT platform | ExoCoBio | Fat stem cells | Acne scars (Kwon 2020), skin aging (Park 2023) | Small controlled trials, 12 weeks |
| ASCEplus Derma Signal Kit SRLV | ExoCoBio | Rose stem cells (plant) | Several skin conditions (2025 case series) | Case series |
| XoGlo | Kimera Labs | Placenta | Keloid scars (Chernoff 2022) | Study without a control group |
| Exovex | Not stated in the study summary | Placenta | Healing after aesthetic procedures (Peredo 2024) | Case series |
| Unnamed exosome blend | Study funded by Benev | Human fat and rose stem cells | Skin aging, compared with PRP (2025) | Non-randomized split-face trial |
| ExoFlo | Direct Biologics | Bone marrow | COVID-19 lung failure (Sengupta 2020, Lightner 2023); phase 3 in ARDS from any cause underway | Phase 2 trial, mixed result |
| EVA-100 | EVast Bio | Umbilical cord | Knee osteoarthritis (Figueroa-Valdés 2025) | Single case, safety only |
| PLEXARIS OS | Exopharm | Donor platelets | Skin wounds in healthy volunteers (Johnson 2023) | Phase 1 trial, no faster healing |
| ECPE formulation | DASAN C&Tech (maker); Cosmedician AP (supplied materials) | Exosomes of unstated source plus seaweed and Thuja extracts | Male pattern hair loss (Amini 2025) | Small randomized trial, 16 weeks |
| UNEX-42 | United Therapeutics | Stem cells | Premature infants at risk of lung disease | Trial stopped for a safety event |
A product listed here is not approved for any use, and a study of it does not mean a clinic's use of it is supported. Products tested only in the lab or in animals are not listed.